Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022


Pfizer Inc. (NYSE: PFE) will share data across its expansive infectious disease portfolio, including company-sponsored and collaborative research studies, spanning both licensed and investigational

Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership


Charles River Laboratories International, Inc. (NYSE: CRL) and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases

BD und BIOCORP unterzeichnen Vertrag, um Konnektivität und Rückverfolgbarkeit für selbst verabreichte Injektionspräparate zu schaffen: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BD und BIOCORP unterzeichnen Vertrag, um Konnektivität und Rückverfolgbarkeit für selbst verabreichte Injektionspräparate zu schaffen


Regulatorische Nachrichten:



BD (Becton, Dickinson and Company) (NYSE: BDX), ein Weltmarktführer in der Medizintechnik, und Biocorp (Paris:ALCOR), ein in Frankreich ansässiger Hersteller von

BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs


Regulatory News:



BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based

Chemed To Report Third-Quarter 2022 Earnings October 31, Related Conference Call To Be Held On November 1:
Chemed To Report Third-Quarter 2022 Earnings October 31, Related Conference Call To Be Held On November 1


Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2022, on Monday, October 31, 2022, following the close of trading on

TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen


Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis

Pharnext Reports First Half 2022 Financial Results
Pharnext Reports First Half 2022 Financial Results
Pharnext Reports First Half 2022 Financial Results
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
Premier, Inc.'s Subsidiary Contigo Health, LLC, Completes Asset Transaction for National Provider Contracts and Licenses to Cost Containment Technology: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc.'s Subsidiary Contigo Health, LLC, Completes Asset Transaction for National Provider Contracts and Licenses to Cost Containment Technology


Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today closed its transaction to acquire key assets from

Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference


POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including

EQS-News: Burcon NutraScience Corp.: Burcon Announces Annual General Meeting Date 
EQS-News: Burcon NutraScience Corp.: Burcon Announces Annual General Meeting Date 
EQS-News: Burcon NutraScience Corp.: Burcon Announces Annual General Meeting Date 
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the

EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022


QuidelOrtho Corporation (NASDAQ: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their

Simulations Plus Releases GastroPlus® Version 9.8.3: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Releases GastroPlus® Version 9.8.3


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its

Agilent Opens Center of Excellence for Dissolution Products:
Agilent Opens Center of Excellence for Dissolution Products


Agilent Technologies Inc. (NYSE: A) today announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. The newly modernized premises will house the

Humana, USAA Launch New Medicare Advantage Plan Tailored to Veterans’ Needs: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana, USAA Launch New Medicare Advantage Plan Tailored to Veterans’ Needs


Humana Inc. (NYSE: HUM) and USAA Life Insurance Company (USAA Life) announced a new Medicare Advantage plan designed with veterans in mind to provide a robust coverage option that complements

Spatial Imaging of 1,000 RNAs and 100 Proteins Using the CosMx Spatial Molecular Imager Published in Nature Biotechnology: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
Spatial Imaging of 1,000 RNAs and 100 Proteins Using the CosMx Spatial Molecular Imager Published in Nature Biotechnology


NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of its first paper describing the